IMR Press / FBL / Volume 21 / Issue 3 / DOI: 10.2741/4412

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Efficacies of treatments for anti-NMDA receptor encephalitis

Show Less
1 Institute of Statistics, National Chiao Tung University, Hsinchu 30010, Taiwan
Academic Editor:Hsiuying Wang
Front. Biosci. (Landmark Ed) 2016, 21(3), 651–663; https://doi.org/10.2741/4412
Published: 1 January 2016
(This article belongs to the Special Issue Anti-NMDA receptor encephalitis and autoimmune diseases)
Abstract

Treatments for anti-N-methyl-D-aspartate (NMDA) receptor encephalitis include immunotherapy with steroids, intravenous immunoglobulin, plasma exchange, or plasmapheresis as first-line treatments, immunotherapy with rituximab or cyclophosphamide as second-line treatments, and tumor removal. In this systematic review, we evaluated previous studies and examined the association between certain microRNAs and anti-NMDA receptor encephalitis to investigate the performance of different treatment combinations. The efficacies of different combinations of treatments classified into the following four categories were compared: (I) intravenous immunoglobulin administration, (II) plasmapheresis or plasma exchange, (III) treatment with rituximab or cyclophosphamide and (IV) tumor removal. Statistical analyses showed that treatment combinations including at least two of these categories resulted in higher efficacy rates than treatment with a single form of therapy. These findings suggest that if a patient is not recovering, converting to other therapies is more likely to result in early recovery than continuing on the original therapy.

Keywords
Anti-NMDA Receptor Encephalitis
Treatment
Efficacy Rate
Share
Back to top